Corvus Pharmaceuticals Stock Today

CRVS Stock  USD 1.76  0.03  1.68%   

Performance

1 of 100

 
Low
 
High
Weak

Odds Of Distress

Less than 10

 
100  
 
Zero
Low
Corvus Pharmaceuticals is selling for under 1.76 as of the 28th of March 2024; that is -1.68 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.76. Corvus Pharmaceuticals has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Corvus Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
23rd of March 2016
Category
Healthcare
Classification
Health Care
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company was incorporated in 2014 and is based in Burlingame, California. Corvus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 49.04 M outstanding shares of which 1.49 M shares are currently shorted by private and institutional investors with about 6.21 trading days to cover. More on Corvus Pharmaceuticals

Moving against Corvus Stock

  0.55MGTX MeiraGTx Holdings PLC Financial Report 9th of May 2024 PairCorr
  0.53SNDL SNDL Inc Buyout TrendPairCorr
  0.48CALT Calliditas Therapeutics Financial Report 21st of May 2024 PairCorr
  0.44DNLI Denali Therapeutics Financial Report 13th of May 2024 PairCorr
  0.42VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr

Corvus Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Corvus Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Corvus Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ChairmanRichard Miller
Thematic IdeaCancer Fighters (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Corvus Pharmaceuticals report their recommendations after researching Corvus Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Corvus Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Corvus Pharmaceuticals. The Corvus consensus assessment is calculated by taking the average forecast from all of the analysts covering Corvus Pharmaceuticals.
Financial Strength
Based on the key indicators related to Corvus Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Corvus Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of Corvus Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities9.7 M6.9 M
Significantly Up
Slightly volatile
Total Assets68.5 M45.6 M
Way Up
Slightly volatile
Total Current Assets26.6 M28 M
Notably Down
Pretty Stable
Corvus Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Corvus Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Corvus Pharmaceuticals' financial leverage. It provides some insight into what part of Corvus Pharmaceuticals' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Corvus Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Corvus Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Corvus Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 1.37 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Corvus Pharmaceuticals has a current ratio of 5.68, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Corvus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Corvus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Corvus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Corvus to invest in growth at high rates of return. When we think about Corvus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Change To Operating Activities

638,554
Corvus Pharmaceuticals (CRVS) is traded on NASDAQ Exchange in USA. It is located in 863 Mitten Road, Burlingame, CA, United States, 94010 and employs 28 people. Corvus Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 88.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Corvus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Corvus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Corvus Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.04 M outstanding shares of which 1.49 M shares are currently shorted by private and institutional investors with about 6.21 trading days to cover. Corvus Pharmaceuticals currently holds about 56.72 M in cash with (23.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Check Corvus Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Corvus Pharmaceuticals retains a total of 49.04 Million outstanding shares. 30% of Corvus Pharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Corvus Ownership Details

Corvus Stock Price Odds Analysis

Attributed to a normal probability distribution, the odds of Corvus Pharmaceuticals jumping above the current price in 90 days from now is more than 93.0%. The Corvus Pharmaceuticals probability density function shows the probability of Corvus Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Corvus Pharmaceuticals has a beta of -0.5936 suggesting as returns on benchmark increase, returns on holding Corvus Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, however, Corvus Pharmaceuticals is likely to outperform the market. Additionally, corvus Pharmaceuticals has an alpha of 0.3372, implying that it can generate a 0.34 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 1.76HorizonTargetOdds Above 1.76
6.63%90 days
 1.76 
93.32%
Based on a normal probability distribution, the odds of Corvus Pharmaceuticals to move above the current price in 90 days from now is more than 93.0 (This Corvus Pharmaceuticals probability density function shows the probability of Corvus Stock to fall within a particular range of prices over 90 days) .

Corvus Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Corvus Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Corvus Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Corvus Pharmaceuticals' value.
InstituionRecorded OnShares
Susquehanna International Group, Llp2023-12-31
220.3 K
Two Sigma Investments Llc2023-12-31
180.7 K
Bridgeway Capital Management, Llc2023-12-31
149.3 K
State Street Corporation2023-12-31
138.4 K
Connor Clark & Lunn Inv Mgmt Ltd2023-12-31
71.2 K
Myda Advisors Llc2023-12-31
71 K
Northern Trust Corp2023-12-31
65 K
Jackson Square Capital, Llc2023-12-31
63.8 K
Hikari Power Ltd2023-12-31
50 K
Orbimed Advisors, Llc2023-12-31
6.9 M
Adams Street Partners Llc2023-12-31
3.3 M
View Corvus Pharmaceuticals Diagnostics

Corvus Pharmaceuticals Historical Income Statement

Corvus Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Corvus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Corvus Pharmaceuticals revenue and expense. Corvus Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Corvus Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Research Development is likely to gain to about 29.2 M in 2024, whereas Gross Profit is likely to drop (158.6 K) in 2024. View More Fundamentals

Corvus Stock Against Markets

Picking the right benchmark for Corvus Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Corvus Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Corvus Pharmaceuticals is critical whether you are bullish or bearish towards Corvus Pharmaceuticals at a given time. Please also check how Corvus Pharmaceuticals' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Corvus Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Funds Screener Now

   

Funds Screener

Find actively-traded funds from around the world traded on over 30 global exchanges
All  Next Launch Module

Corvus Pharmaceuticals Corporate Directors

Corvus Pharmaceuticals corporate directors refer to members of a Corvus Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Corvus Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Corvus Pharmaceuticals' board members must vote for the resolution. The Corvus Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Ian ClarkIndependent DirectorProfile
Elisha GouldIndependent DirectorProfile
Steve KrognesIndependent DirectorProfile
Peter ThompsonIndependent DirectorProfile

How to buy Corvus Stock?

Before investing in Corvus Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Corvus Pharmaceuticals. To buy Corvus Pharmaceuticals stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Corvus Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Corvus Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Corvus Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Corvus Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Corvus Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.

Already Invested in Corvus Pharmaceuticals?

The danger of trading Corvus Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Corvus Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Corvus Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Corvus Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Corvus Pharmaceuticals is a strong investment it is important to analyze Corvus Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Corvus Pharmaceuticals' future performance. For an informed investment choice regarding Corvus Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corvus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Corvus Stock analysis

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Commodity Directory
Find actively traded commodities issued by global exchanges
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Is Corvus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corvus Pharmaceuticals. If investors know Corvus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corvus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Return On Assets
(0.26)
Return On Equity
(0.57)
The market value of Corvus Pharmaceuticals is measured differently than its book value, which is the value of Corvus that is recorded on the company's balance sheet. Investors also form their own opinion of Corvus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corvus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corvus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corvus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corvus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corvus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corvus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.